Add like
Add dislike
Add to saved papers

Non-invasively Discriminating the Pathological Subtypes of Non-small Cell Lung Cancer with Pretreatment 18 F-FDG PET/CT Using Deep Learning.

Academic Radiology 2023 April 27
RATIONALE AND OBJECTIVES: To develop an end-to-end deep learning (DL) model for non-invasively predicting non-small cell lung cancer (NSCLC) pathological subtypes based on 18 F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) images, and to explore the potential value of DL technology.

MATERIALS AND METHODS: Preoperative 18 F-FDG PET/CT images of 189 patients with NSCLC were retrospectively collected. The whole cohort was randomly divided into a training cohort, a validation cohort, and an internal/extended test cohort at the ratio of 6:2:2 after preprocessing the images. In the training and validation cohorts, seven DL models-Shufflenet, VGG16, Googlenet, Inception v3, Resnet50, Densenet201, and Mobilenet v2-were trained and optimized. The generalization ability and clinical utility of the optimal model were evaluated in the internal and extended test cohorts. Moreover, Spearman's correlation analysis was used to evaluate the correlation between DL features and traditional radiological features such as tumor size and maximum standardized uptake values (SUVmax).

RESULTS: Some DL features were significantly correlated with SUVmax and tumor size (P < 0.05). The Mobilenet v2 model achieved the best performance during the model development and validation phases. In the internal test group (area under the receiver operating characteristic curve [AUC]: 0.744, area under the precision-recall curve [AP]: 0.759) and extended test group (AUC: 0.767, AP: 0.768), the Mobilenet v2 model showed good generalization ability and reproducibility. Meanwhile, the decision curve analysis revealed that patients can benefit from the decisions made based on the Mobilenet v2 model.

CONCLUSION: DL models offer great potential for classifying NSCLC pathological subtypes. Specifically, the Mobilenet v2 model performs well at end-to-end non-invasive pathological subtype stratification of NSCLC.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app